IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME TUMORS: FROM BASIC TO CLINICAL TRIAL STUDIES

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ALIZADEH LEILA; GORIZAN ALI; AKBARI DANA MARYAM; GHAEMI AMIR

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Neuroscience Journal of Shefaye Khatam Year:2015 | Volume:3 | Issue:2 Page(s): 77-84

Download Full-Text

Persian Verion

View:

1,028

Download:

Cites:

Information Journal Paper

Title

IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME TUMORS: FROM BASIC TO CLINICAL TRIAL STUDIES

Author(s)

ALIZADEH LEILA | GORIZAN ALI | AKBARI DANA MARYAM | GHAEMI AMIR | Issue Writer Certificate

Keywords

GLIOBLASTOMAQ3

CYTOKINESQ3

IMMUNITYQ3

Abstract

Introduction: GLIOBLASTOMA multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults and is one of a group of tumors referred to as gliomas. The National Cancer Institute estimates that 23, 000 adults were diagnosed with GBM every year in USA, and less than 5% survive 5 years post-diagnosis. Thus, novel therapeutic strategies to target and kill GBM cells are desperately needed to increase the efficiency of therapy. Immunotherapy has the potential of inducing the IMMUNITY to remove GBM cells that might have spread throughout the central nervous system.Conclusion: In current review, the latest developments in preclinical immunotherapy for glioma will be discussed, which involve the local delivery of proinflammatory CYTOKINES, such as Flt3L, Type I IFNs, IL-2, IL-4, and IL-12 using gene therapy carriers and neural stem cells, or the blockade of immune-suppressive mediators, such as TGF beta, FasL and phosphorylated STAT3. New immunotherapeutic strategies have also been evaluated in clinical trials applied in GBM patients, which makes it a promising tool in the future treatments for GBM.

Cites

THE EFFECT OF LIPOPOLYSACCHARIDE PRETREATMENT ON TRAUMA-INDUCED DARK NEURONS IN THE HIPPOCAMPUS

References

No record.

Cite

APA: Copy

ALIZADEH, LEILA, GORIZAN, ALI, AKBARI DANA, MARYAM, & GHAEMI, AMIR. (2015). IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME TUMORS: FROM BASIC TO CLINICAL TRIAL STUDIES. NEUROSCIENCE JOURNAL OF SHEFAYE KHATAM, 3(2), 77-84. SID. https://sid.ir/paper/258020/en

Vancouver: Copy

ALIZADEH LEILA, GORIZAN ALI, AKBARI DANA MARYAM, GHAEMI AMIR. IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME TUMORS: FROM BASIC TO CLINICAL TRIAL STUDIES. NEUROSCIENCE JOURNAL OF SHEFAYE KHATAM[Internet]. 2015;3(2):77-84. Available from: https://sid.ir/paper/258020/en

IEEE: Copy

LEILA ALIZADEH, ALI GORIZAN, MARYAM AKBARI DANA, and AMIR GHAEMI, “IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME TUMORS: FROM BASIC TO CLINICAL TRIAL STUDIES,” NEUROSCIENCE JOURNAL OF SHEFAYE KHATAM, vol. 3, no. 2, pp. 77–84, 2015, [Online]. Available: https://sid.ir/paper/258020/en

Related Journal Papers